Recently in CME Category

Study Finds CME Funding Doesn't Create Bias

| No Comments
A new study by four researchers from the Cleveland Clinic showed that industry support of continuing medical education created no bias among participants.

The study is available here:CME_Kawczak_Acad Med.pdf

Healthcare industry expert Peter Pitts has enlightening comments on the paper in his DrugWonks blog on the Center for Medicine in the Public Interest Web site. You can view his comments here: http://drugwonks.com/blog_post/show/7182

We invite your comments! 

MM&M Profiles Tom Sullivan, a Forceful Defender of CME

| No Comments
The February issue of MM&M magazine spotlights Policymed.com blogger Tom Sullivan.
Read the article here:sullivan_mmandm_feb1_10.pdf

Your comments are encouraged.
Interesting discussion on why corporate backing of medical research is NOT a bad thing:

Corporate Backing for Research? Get Over It!
John Tierney in the New York Times, Jan. 25, 2010

Hyperscrutiny of Academic-Industrial Relationships: Potential for Unintended Consequences
Tom Sullivan's Policy and Medicine Blog, Jan. 27, 2010

More thoughts on the issue on Tom Sullivan's Policy and Medicine Blog

Read about it and join the discussion here.





In one of her final acts as NJ Attorney General, Anne Milgram's office has issued a new report, "Physician Compensation Arrangements," recommending limitations to physician-industry relationships for state agencies that go above and beyond guidelines outlined by PhRMA and other organizations.

Although this proposal comes from the office of the outgoing Attorney General, and would be an unlikely top priority for the Christie Administration, many of the recommendations could be implemented in the Garden State without legislation. Recommendations that could soon be implemented include:

  • Banning all food, entertainment, etc., paid for by industry, going above and beyond the PhRMA guidelines
  • Requirement that doctors report financial compensation of $200 or more from the pharmaceutical industry over the past two years
  • Require 25% of physician CME be obtained from evidence-based educational programs or academic detailing (government controlled CME)
  • Directive that the NJ Legislature limit commercial use of prescriber data, similar to requirements enacted in New Hampshire and other states
To read a detailed outline and the full report, click here

AAFP Defends Pharma Participation in CME

| No Comments
In a recent editorial, the American Academy of Family Physicians (AAFP) cited the Macy Report, the AMA's CEJA report, JAMA, and the massive IOM report, saying "These reports and opinions start from a basic premise that any engagement with the pharmaceutical industry is a conflict and must be eliminated. But the AAFP does not accept this "good money/bad money" hypothesis, and neither do most professional associations. Pharmaceutical and other companies have a significant role to play in informing health care professionals about the availability and proper use of medications and other therapies."  See full article below.
Download PDF:  AFFP_CME_Oct09.pdf

View report.

As the controversy around the commercial support of CME continues, ACCME is considering significant policy changes that could dramatically change industry support of both certified and promotional education programs. For example, one recent proposal would prohibit faculty thought leaders from participating in both CME and promotional programs.  View responses.
For more information contact:
Brad Bednarz bbednarz@visiblep.com
Marty Cearnal mcearnal@jobson.com
The public debate on these issues has reached a critical juncture and your participation can help shape the debate. Help support our industry by insuring that our Nation's clinicians and patients are empowered with the latest developments in medical information.

Thank you

John Kamp
Executive Director
Coalition for Healthcare Communication
On Tuesday, April 28, the Institute of Medicine (IOM) made public its sweeping recommendations on "Conflict of Interest in Medical Research, Education and Practice."

While the tone of the IOM press material and draft report suggests a rather modest call for change in the relationships among the industry, organized medicine and prescribers, the press statements of the participants and a careful reading of the report (over 350 pages) illuminate an intent by the Committee to aggressively limit the role of the industry in organized medicine and policy making.


AMA's CEJA Report Revised Before June 14th AMA Meeting
Coalition Encourages Discussion and Comments


In response to feedback on its original report, the AMA's Council on Ethical and Judicial Affairs (CEJA) on June 9th recommended important revisions to its report, "Financial Relationships with Industry in Continuing Medical Education" to be considered for submission to the AMA House of Delegates on June 14th.

The CEJA recommendation and specific, more recent feedback acted upon by the CEJA are available here:

CEJA Recommendation:
CEJA_Recommendation_Jun09.pdf

Analysis and Recommendation by John Kamp on behalf of the Coalition:
CEJA_Recomendations_Kamp_Jun8_09.pdf

Recommendation by the Council on Medical Specialty Societies (CMSS)
CMSS_Response_CEJA_Jun09.pdf

Recommendation by The Alliance for Continuing Medical Education
Alliance_Response_CEJA_Jun09.pdf

If you would like to discuss these important CME issues, please visit the Coalition's LinkedIn Group: http://www.linkedin.com/groups?gid=1981721

The Coalition and others will also be producing comments, and they will be announced on our LinkedIn Group

For more information please contact:

Brad Bednarz bbednarz@visiblep.com
Marty Cearnal mcearnal@jobson.com
Mark Schaffer mark.schaffer@ppscme.com
John Kamp jkamp@cohealthcom.org

About this Archive

This page is an archive of recent entries in the CME category.

Conflict of Interest is the next category.

Find recent content on the main index or look in the archives to find all content.